Phys · renal
Diabetic Kidney Disease
Also known as DKD · diabetic nephropathy · diabetic kidney disease · Kimmelstiel-Wilson disease · nodular glomerulosclerosis · diabetic glomerulosclerosis · microalbuminuria · diabetic renal disease · diabetic kidney failure
Consultant-physician-depth guide to diabetic kidney disease (DKD) — the leading cause of end-stage kidney disease worldwide. Covers the hyperglycaemia to AGE to fibrosis pathophysiology, Mogensen five-stage natural history, screening with annual albumin-to-creatinine ratio, evidence-based management (SGLT2 inhibitors per CREDENCE/DAPA-CKD/EMPA-KIDNEY, ACEi/ARB per RENAAL/IDNT, finerenone per FIDELIO-DKD, multifactorial intervention per Steno-2), normoalbuminuric DKD, and renal biopsy indications. Structured for FRACP DWE and DCE preparation.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- Rapidly falling eGFR in known DKD — exclude superimposed acute or alternative process (RPGN, obstruction, nephrotoxin); consider renal biopsy
- Active urinary sediment — dysmorphic red cells, red cell casts — DKD has bland urine; this mandates a search for superimposed glomerulonephritis
- Nephrotic-range proteinuria without diabetic retinopathy in short-duration diabetes — biopsy to confirm diagnosis
- Hyperkalaemia with ECG changes — medical emergency; calcium, insulin-dextrose, treat acidosis, review RAAS and SGLT2i
- Severe refractory volume overload with pulmonary oedema — may need urgent dialysis
- Hypoglycaemia in a previously stable patient — falling eGFR reduces insulin clearance; reassess all hypoglycaemic agents
- Acute kidney injury on DKD — common with intercurrent illness, contrast, or NSAIDs; hold sick-day medications and seek the trigger
Diabetic Kidney Disease
The answer first
Diabetic kidney disease (DKD) is the chronic kidney injury caused by diabetes — structurally a combination of glomerular basement membrane thickening, mesangial expansion with Kimmelstiel-Wilson nodules, afferent and efferent arteriolar hyalinosis, and tubulointerstitial fibrosis. Clinically it is the leading single cause of end-stage kidney disease (ESKD) worldwide, responsible for around 40 to 50% of new dialysis patients in Australia, the UK and the US [2].
The two questions that dominate DKD management: [1]
- Is this really DKD, or is there a superimposed or alternative process? Classic DKD in a patient with long-standing diabetes and retinopathy needs no biopsy. Atypical features — rapid decline, haematuria, active sediment, short diabetes duration, no retinopathy in T1DM — demand a renal biopsy to exclude a treatable glomerulonephritis.
- How do I slow progression and reduce the cardiovascular death that kills most of these patients before they reach dialysis? [1]
The management mandate, in priority order: [1]
- Start an SGLT2 inhibitor in every patient with T2DM and eGFR greater than or equal to 20 with albuminuria or eGFR-based CKD, irrespective of glycaemia — CREDENCE, DAPA-CKD and EMPA-KIDNEY are the three pillars of this mandate [3][4][5].
- Maximise RAAS blockade — ACE inhibitor or ARB (never both) at maximally tolerated dose for any patient with albuminuria, the foundation laid by RENAAL, IDNT and ADVANCE [7][8][9].
- Add finerenone in T2DM CKD with albuminuria on top of maximal RAAS blockade — FIDELIO-DKD [6].
- Control blood pressure, glycaemia and lipids — the multifactorial Steno-2 model halves cardiovascular events over the long term [10].
- Prevent and manage CKD complications — anaemia, CKD-MBD, acidosis, hyperkalaemia, volume overload.
- Prepare for kidney replacement therapy early and offer a conservative care pathway where dialysis will not benefit.
The single most important exam principle: cardiovascular disease kills more DKD patients than kidney failure does. A stage 3 DKD patient is far more likely to die of an MI than reach dialysis. Statin and BP control are non-negotiable, and a DKD patient without a statin is a long-case fail. [1]
References11ShowHide
- [1]Stevens PE, Levin A Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline Ann Intern Med, 2013.PMID 23732715
- [2]Alicic RZ, Rooney MT, Tuttle KR Diabetic Kidney Disease: Challenges, Progress, and Possibilities Clin J Am Soc Nephrol, 2017.PMID 28522654
- [3]Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med, 2019.PMID 30990260
- [4]Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med, 2020.PMID 32970396
- [5]Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in Patients with Chronic Kidney Disease N Engl J Med, 2023.PMID 36331190
- [6]Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes N Engl J Med, 2020.PMID 33264825
- [7]Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med, 2001.PMID 11565518
- [8]Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med, 2001.PMID 11565517
- [9]Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial Lancet, 2007.PMID 17765963
- [10]Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med, 2003.PMID 12556541
- [11]Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure JAMA, 2011.PMID 21482743